Piscataway, NJ – Sabinsa Corporation has successfully ended its patent infringement lawsuit against Olive Lifesciences Pvt. Ltd.
On April 5, the United States District Court in New Jersey entered a judgment awarding Sabinsa over $850,000 in damages, enhanced damages, attorney’s fees, costs, and interest, according to a statement from the company.
On June 8, 2016, Sabinsa filed suit against Olive for willful infringement of U.S. Patent No. 6,653,327, according to Sabinsa founder Dr. Muhammed Majeed. The ’327 Patent protects Sabinsa’s novel methods and formulations for tetrahydrocurcuminoids (THCs).
The judgment concludes that the ’327 Patent is valid, enforceable, and properly issued by the U.S. Patent and Trademark Office. Sabinsa has patents related to THCs in the United States, Europe, Australia, New Zealand, and other locations. In the United States, Sabinsa has successfully litigated willful infringement of the ’327 patent and has obtained judgments against other infringers.
Sabinsa has a well-earned reputation for strong enforcement of its intellectual property rights and will continue to pursue all available legal remedies to protect those rights, Dr. Majeed stated. “As a pioneer in the industry, Sabinsa has researched and developed many innovative products used by the nutritional supplement industry,” said Dr. Majeed. “The success has spawned many imitators, and Sabinsa will not hesitate to enforce its patents and other intellectual property,” he added.